When was Cellvie founded?

Cellvie was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Cellvie located?

Cellvie is headquartered in Houston, United States.

Who is the current CEO of Cellvie?

Alexander Schueller of Cellvie. They have also founded 1 company.

How many employees does Cellvie have?

As of Sep 30, 2026, the latest employee count at Cellvie is 11.

Is Cellvie a funded company?

Cellvie is a funded company, having raised a total of $15.5M across 4 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 24, 2020.

When was the latest funding round of Cellvie?

Cellvie's latest funding was a $***** Seed round on Sep 09, 2025, with participation from 3 investors. Its primary sector is Nephrology. In United States, the Nephrology sector has seen $393M in funding in 2026 to date.

Where does Cellvie rank among its competitors?

Cellvie ranks 121st amongst 425 active competitors, of which 129 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Rejuvenate Bio, which secured $19.5M in Jun, 2026.

Who are the top competitors of Cellvie?

Cellvie's top competitors include argenx, Vor Biopharma and Tenaya Therapeutics. Among them, Rejuvenate Bio secured the most recent funding round in June, 2026.

Cellvie - 2026 Company Profile, Team, Funding & Competitors

Cellvie is a seed company based in Houston (United States), founded in 2020 by Alexander Schueller. It operates as a Developer of cell-derived therapeutics solutions for the treatment of cardiac health, stroke & kidney transplantation. Cellvie has raised $15.5M in funding from Taiho Ventures and Kizoo. The company has 425 active competitors, including 129 funded and 119 that have exited. Its top competitors include companies like argenx, Vor Biopharma and Tenaya Therapeutics.

Company Details

Developer of cell-derived therapeutics solutions for the treatment of cardiac health, stroke & kidney transplantation. The company has developed cell-based medicines by using the therapeutic potential of mitochondria. Its proprietary technology generates chemical energy by using the cell's biochemical reactions that help in the treatment of ischemia-reperfusion injury or reoxygenation injury.

Key Metrics

Founded Year

2020

Location

Houston, United States

Stage

Seed

Total Funding

$15.5M in 4 rounds

Latest Funding Round

Seed, Sep 09, 2025, $*****

Investors

Taiho Ventures & 3 more

Ranked

121^st among 425 active competitors

Employee Count

11 as on Sep 30, 2026

Similar Companies

Tenaya Therapeutics & 415 more

View Cellvie's full profile

Cellvie has raised a total funding of $15.5M over 4 rounds. Its first funding round was on Sep 24, 2020. Its latest funding round was a Seed round on Sep 09, 2025 for $*****. 3 investors participated in its latest round. Cellvie has 4 institutional investors.

Here is the list of recent funding rounds of Cellvie:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 09, 2025	2609119	Seed	3135570	7456800	1653476	6876631
Feb 06, 2023	9051200	Seed	6388520	1438212	3393190	Kizoo
Jan 25, 2021	9424404	Seed	7507956	6389548	Kizoo	8006188

Access funding benchmarks and valuations. Sign up today!

View details of Cellvie's funding rounds and investors

The founders of Cellvie is Alexander Schueller. Alexander Schueller is the CEO of Cellvie.

Here are the details of Cellvie's key team members:

Alexander Schueller: Founder & CEO of Cellvie.
Contact Info: 1 email address

View details of Cellvie's Founder profiles and Board Members

Cellvie's employee count trend

Cellvie has 11 employees as of Sep 26. Here is Cellvie's employee count trend over the years:

Uncover Cellvie's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cellvie include argenx, Vor Biopharma and Tenaya Therapeutics. Here is the list of Top 10 competitors of Cellvie, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	76/100
2nd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	69/100
3rd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, Fidelity Investments & 7 others	66/100
4th	Structure 2017, San Francisco (United States), Public	Developer of oral small molecule drugs for chronic diseases	$191M	BVF Partners, Janus Henderson Investors & 17 others	65/100
5th	Esperion Therapeutics 1998, Ann Arbor (United States), Acquired	Developer of lipoprotein cholesterol (LDL-C) lowering therapies	$107M	Alta Partners, Longitude Capital & 16 others	63/100
6th	Kiniksa Pharmaceuticals 2015, Lexington (United States), Public	Developer of therapeutics for multiple diseases treatment	$320M	Fidelity Investments, Sofinnova Investments ... & 8 others	65/100
7th	Marea Therapeutics 2022, San Francisco (United States), Acquired	Provider of therapeutics for cardiometabolic diseases	$65.4M	Alpha Wave Global, Sofinnova Investments & 1 others	63/100
8th	Rejuvenate Bio 2018, San Diego (United States), Series A	Developer of gene therapies for treating chronic and age-related diseases	$34M	VCapital, Digitalis Ventures & 12 others	63/100
9th	Radius Health 2003, Boston (United States), Acquired	Biopharmaceutical company focused on bone health and related therapeutic areas	$213M	MPM BioImpact, Wellcome & 14 others	62/100
10th	Innovent Bio 2011, Suzhou (China), Public	Developer of antibody therapeutics for multiple diseases	$535M	Eight Roads Ventures, Lilly Asia Ventures ... & 24 others	62/100
121st	Cellvie 2020, Houston (United States), Seed	Developer of cell-derived therapeutics solutions for the treatment of cardiac health, stroke & kidney transplantation	$15.5M	Taiho Ventures, Kizoo & 2 others	40/100